A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma
The case provides valuable insights that could influence future treatment strategies for older patients with advanced cholangiocarcinoma who are unsuitable for chemotherapy. The dose-individualized chemotherapy-free regime of lenvatinib and tislelizumab might be used in similar cases to improve their outcomes.
Authors
- Ke Cheng (ORCID: https://orcid.org/0000-0002-6034-8872)
- Dan Cao (ORCID: https://orcid.org/0000-0002-6709-4932)
- Pei Zhang (ORCID: https://orcid.org/0009-0009-5063-3512)
- Xin Wang (ORCID: https://orcid.org/0009-0009-0444-1704)
- Ruizhen Li
Institutions
- Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.3389/fphar.2024.1447582
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sichuan University
- West China Hospital, Sichuan University